We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Meta analysis of the efficacy and safety of apatinib in treatment of patients with advanced gastric cancer.
- Authors
LI Chunxing; LIU Hua; YOU Kai
- Abstract
Objective: To systematically evaluate the efficacy and safety of apatinib in treatment of patients with advanced gastric cancer (AGC), so as to provide evidence-based reference for clinical medication. Methods: The pertinent randomized controlled trials (RCT) about apatinib and conventional therapy in the treatment of AGC were retrieved from Cochrane library, PubMed, Chinese National Knowledge Infrastructure (CNKI) and Wanfang Data Digitalization Database. The quality of the included studies were evaluated according to modified Jadad scale. Then, the related data was extracted and meta analysis was performed by using RevMan 5.3 statistical software. Results: A total of 20 RCT were included, involving 1379 patients. The results of meta analysis showed that objective response rate (ORR), disease control rate (DCR) and overall survival (OS) were sig-nificantly increased, the progression free survival (PFS) was ramarkably prolonged and patients' quality of life was significantly improved in the apatinib treatment group, as compared with the control group (P<0.01, P<0.001). Rates of adverse drug reactions (ADRs) of hypertension and proteinuria increased with statistical significance in the apatinib treatment group, as compared with those in the control group. The rates of other ADRs was not statistically significant. Conclusion: Apatinib showed good therapeutic efficacy in the first or second or above-line treatment of AGC and could effectively improve ORR, DCR, OS, patient life quality, and prolong PSF. However, one should be highly aware of such ADRs as hypertension and proteinuria. In consideration of low quality of some included randomized controlled trials, more high-quality and large-sample randomized controlled trials are expected to support this conclusion.
- Publication
Pharmaceutial Care & Research, 2019, Vol 19, Issue 1, p41
- ISSN
1671-2838
- Publication type
Article
- DOI
10.5428/pcar20190111